Boston Scientific Scimed Ether-Containing Radiopaque Hydrogel Patent
Summary
Boston Scientific Scimed, Inc. filed patent application US20260108635A1 on October 21, 2025 (Application No. 19364325) for iodinated polyamino compounds comprising a polyamino moiety coupled to an iodinated aromatic moiety through an ether linkage, optionally including an amide group. The application also covers systems for forming hydrogels using these compounds with a reactive polymer that forms crosslinks, and methods of treatment using such systems. Inventors are Rick William Dorn, Cristian Parisi, Joseph Thomas Delaney Jr., and Yen-Hao Hsu.
“In some aspects, the present disclosure provides iodinated polyamino compounds that comprise a polyamino moiety that is coupled to an iodinated aromatic moiety through a linkage that comprises an ether group, and optionally an amide group.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
Boston Scientific Scimed, Inc. has filed a patent application (US20260108635A1) covering ether-containing radiopaque polyamino crosslinkers and medical hydrogels formed therefrom. The application claims iodinated polyamino compounds where a polyamino moiety is linked to an iodinated aromatic moiety via an ether group (optionally with an amide group), as well as crosslinking systems and treatment methods.
For competitors in the medical device and biomaterials space, this application signals Boston Scientific's development of novel radiopaque hydrogel materials with potential applications in minimally invasive or embolization procedures. R&D teams working on similar crosslinked biomaterials should review the disclosed CPC classifications (A61K 49/0442, A61K 49/0457, C08G 69/10) to assess potential freedom-to-operate considerations.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM
Application US20260108635A1 Kind: A1 Apr 23, 2026
Assignee
Boston Scientific Scimed, Inc.
Inventors
Rick William Dorn, Cristian Parisi, Joseph Thomas Delaney, JR., Yen-Hao Hsu
Abstract
In some aspects, the present disclosure provides iodinated polyamino compounds that comprise a polyamino moiety that is coupled to an iodinated aromatic moiety through a linkage that comprises an ether group, and optionally an amide group. Other aspects of the present disclosure pertain to systems for forming hydrogels that comprise (a) an iodinated polyamino compound that comprises a polyamino moiety that is coupled to an iodinated aromatic moiety through a linkage that comprises an ether group, and optionally an amide group, and (b) a reactive polymer that forms crosslinks with the iodinated polyamino compound. Still other aspects of the present disclosure pertain to crosslinked products formed from such systems and methods of treatment using such systems.
CPC Classifications
A61K 49/0442 A61K 49/0457 C08G 69/10
Filing Date
2025-10-21
Application No.
19364325
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.